Pharma Giants Pour Billions into Pancreatic Cancer Treatments

The pharmaceutical industry is pouring billions into developing treatments for pancreatic cancer, particularly those targeting the KRAS G12D mutation. Merck secured rights to a KRAS G12D inhibitor from CymaBay Therapeutics in a deal worth $2.13 billion, including an upfront payment of $400 million. This follows Bayer's acquisition of a KRAS G12D inhibitor from Kumquat Biosciences for up to $1.3 billion.

Despite the high stakes, there is currently no approved therapy that selectively targets this specific mutation. The KRAS protein surface is smooth, making it difficult to find a distinct binding pocket for drugs to attach to, a challenge dubbed 'undruggable' since 1982.

However, recent approaches have become more diverse. Beyond traditional small-molecule inhibitors, drugs that directly target the active state of the KRAS protein are being developed, as well as protein degraders which bind to G12D and recruit the cell's protein degradation system to eliminate the target protein itself.